Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Biogen (NASDAQ:BIIB) reported strong Q1 earnings, beating expectations. However, they cut their FY2026 EPS guidance. Analysts have mixed opinions on buying BIIB stock.
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.9% year on year to $2.48 billion. Its...
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before the bell. Here’s what you need to know. Biogen beat analysts’ revenue ex...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Check out the companies making headlines yesterday: Cadence Design Systems (NASDAQ:CDNS): Electronic design automation company Cadence Design Systems (NASDAQ...
Biogen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 19.7%. The stock now trades at $183.50, marking a 25.5% ga...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Novav...
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.6% in the afternoon session after the company received an analyst upgrade from Wells F...
